

Jin Seok Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1910206/publications.pdf>

Version: 2024-02-01

352
papers

6,149
citations

94269

37
h-index

106150

65
g-index

357
all docs

357
docs citations

357
times ranked

8027
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6027-6032. | 0.8 | 312 |
| 2 | A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400. | 5.1 | 285 |
| 3 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. <i>Leukemia</i> , 2017, 31, 2443-2448. | 3.3 | 259 |
| 4 | Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. <i>Haematologica</i> , 2018, 103, 2088-2096. | 1.7 | 187 |
| 5 | Protein Kinase CK2± as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2007, 13, 1019-1028. | 3.2 | 184 |
| 6 | Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. <i>Annals of Thoracic Surgery</i> , 2001, 71, 290-294. | 0.7 | 129 |
| 7 | Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965. | 0.6 | 121 |
| 8 | Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. <i>Annals of Hematology</i> , 2014, 93, 1895-1901. | 0.8 | 115 |
| 9 | Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). <i>BMC Cancer</i> , 2011, 11, 321. | 1.1 | 107 |
| 10 | AMPK±ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2781-2794. | 3.2 | 104 |
| 11 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group. <i>European Journal of Cancer</i> , 2013, 49, 3486-3496. | 1.3 | 103 |
| 12 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial. <i>European Journal of Cancer</i> , 2012, 48, 3223-3231. | 1.3 | 99 |
| 13 | Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757. | 0.7 | 98 |
| 14 | Clinical profiles of multiple myeloma in Asia±An Asian Myeloma Network study. <i>American Journal of Hematology</i> , 2014, 89, 751-756. | 2.0 | 88 |
| 15 | Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. <i>Cell Transplantation</i> , 2010, 19, 1237-1246. | 1.2 | 84 |
| 16 | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). <i>Journal of Hematology and Oncology</i> , 2012, 5, 49. | 6.9 | 83 |
| 17 | Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604. | 2.0 | 76 |
| 18 | Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. <i>BMC Cancer</i> , 2010, 10, 321. | 1.1 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 135, 912-920. | 0.6 | 73 |
| 20 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373. | 2.2 | 70 |
| 21 | Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. <i>Blood Advances</i> , 2018, 2, 2176-2185. | 2.5 | 65 |
| 22 | Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer. <i>Annals of Oncology</i> , 2010, 21, 1285-1289. | 0.6 | 63 |
| 23 | Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. <i>European Journal of Cancer</i> , 2002, 38, 75-81. | 1.3 | 62 |
| 24 | Radiotherapy for solitary plasmacytoma of bone and soft tissue. <i>Annals of Hematology</i> , 2012, 91, 1785-1793. | 0.8 | 62 |
| 25 | Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells. <i>Autophagy</i> , 2017, 13, 761-762. | 4.3 | 60 |
| 26 | Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 463-470. | 2.0 | 55 |
| 27 | When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?. <i>Annals of Oncology</i> , 2010, 21, 1058-1063. | 0.6 | 55 |
| 28 | Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Annals of Hematology</i> , 2010, 89, 563-568. | 0.8 | 54 |
| 29 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e543-e553. | 2.2 | 53 |
| 30 | Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214. | 1.1 | 51 |
| 31 | PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. <i>Oncotarget</i> , 2019, 8, e1544442. | 2.1 | 51 |
| 32 | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551. | 0.8 | 50 |
| 33 | Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 118-125. | 2.0 | 49 |
| 34 | Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243. | 2.3 | 47 |
| 35 | Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. <i>Annals of Hematology</i> , 2015, 94, 275-282. | 0.8 | 45 |
| 36 | Prognostic implications of the immunophenotype in biphenotypic acute leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 700-709. | 0.6 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57. | 0.7 | 41 |
| 38 | Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 25. | 6.9 | 41 |
| 39 | PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 66. | 3.5 | 39 |
| 40 | Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. <i>Medical Oncology</i> , 2012, 29, 1179-1185. | 1.2 | 38 |
| 41 | Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. <i>British Journal of Haematology</i> , 2004, 124, 166-178. | 1.2 | 37 |
| 42 | Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. <i>Journal of Hematology and Oncology</i> , 2011, 4, 34. | 6.9 | 37 |
| 43 | Solution structure of the ZÎ ² domain of human DNA-dependent activator of IFN-regulatory factors and its binding modes to B- and Z-DNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 6921-6926. | 3.3 | 36 |
| 44 | Myeloperoxidase Expression as a Potential Determinant of Parthenolide-Induced Apoptosis in Leukemia Bulk and Leukemia Stem Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 389-400. | 1.3 | 34 |
| 45 | Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. <i>American Journal of Hematology</i> , 2017, 92, 1280-1286. | 2.0 | 34 |
| 46 | Transfusion-Associated Iron Overload as an Adverse Risk Factor for Transplantation Outcome in Patients Undergoing Reduced-Intensity Stem Cell Transplantation for Myeloid Malignancies. <i>Acta Haematologica</i> , 2008, 120, 182-189. | 0.7 | 33 |
| 47 | Incidence and risk factors for carbapenem- and multidrug-resistant <i>Acinetobacter baumannii</i> bacteremia in hematopoietic stem cell transplantation recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 81-88. | 1.5 | 33 |
| 48 | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2012, 53, 1515-1524. | 0.6 | 32 |
| 49 | Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1020-1026. | 0.6 | 30 |
| 50 | Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma. <i>Oncotarget</i> , 2017, 8, 87317-87328. | 0.8 | 30 |
| 51 | Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 87-96. | 2.5 | 29 |
| 52 | Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of the RISK Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1773-1779. | 2.0 | 29 |
| 53 | Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210. | 0.7 | 28 |
| 54 | Risk Factors for Progression from Cytomegalovirus Viremia to Cytomegalovirus Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 881-886. | 2.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | A new prognostic model using absolute lymphocyte count in patients with primary central nervous system lymphoma. <i>European Journal of Cancer</i> , 2016, 57, 127-135. | 1.3 | 28 |
| 56 | Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 352. | 0.7 | 27 |
| 57 | Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546. | 0.8 | 26 |
| 58 | Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes. <i>PLoS ONE</i> , 2014, 9, e86933. | 1.1 | 26 |
| 59 | Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387. | 1.3 | 26 |
| 60 | Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature. <i>Gut and Liver</i> , 2014, 8, 109-112. | 1.4 | 26 |
| 61 | Acute promyelocytic leukemia with insertion of PML exon 7a and partial deletion of exon 3 of RARA: a novel variant transcript related to aggressive course and not detected with real-time polymerase chain reaction analysis. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 103-107. | 1.0 | 25 |
| 62 | Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2067-2074. | 0.6 | 25 |
| 63 | PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGF β Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 1644-1655. | 3.2 | 25 |
| 64 | Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. <i>Anticancer Research</i> , 2015, 35, 3081-9. | 0.5 | 25 |
| 65 | 8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality. <i>Cancer Genetics and Cytogenetics</i> , 2008, 181, 93-99. | 1.0 | 24 |
| 66 | Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179. | 0.4 | 24 |
| 67 | Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen. <i>BMC Cancer</i> , 2016, 16, 613. | 1.1 | 24 |
| 68 | Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 2947-2958. | 3.2 | 24 |
| 69 | ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 85. | 3.5 | 23 |
| 70 | Patterns of care and treatment outcomes for primary thyroid lymphoma: a single institution study. <i>Radiation Oncology Journal</i> , 2013, 31, 177. | 0.7 | 23 |
| 71 | Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study. <i>Annals of Hematology</i> , 2016, 95, 337-344. | 0.8 | 22 |
| 72 | Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 1247-1252. | 1.2 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean Journal of Internal Medicine, 2020, 35, 25-40. | 0.7 | 22 |
| 74 | Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2008, 49, 88-94. | 0.6 | 21 |
| 75 | The Modified Glasgow Prognostic Scores as a Predictor in Diffuse Large B Cell Lymphoma Treated with R-CHOP Regimen. Yonsei Medical Journal, 2014, 55, 1568. | 0.9 | 21 |
| 76 | Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal of Korean Medical Science, 2016, 31, 1516. | 1.1 | 21 |
| 77 | Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Bone Marrow Transplantation, 2019, 54, 1361-1368. | 1.3 | 20 |
| 78 | Myeloperoxidase Expression in Acute Myeloid Leukemia Helps Identifying Patients to Benefit from Transplant. Yonsei Medical Journal, 2012, 53, 530. | 0.9 | 19 |
| 79 | Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma. Transplant Infectious Disease, 2015, 17, 679-687. | 0.7 | 19 |
| 80 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 477 by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. Blood, 2011, 118, 2044-2044. | 0.6 | 19 |
| 81 | Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. European Journal of Haematology, 2022, 109, 205-214. | 1.1 | 19 |
| 82 | The role of radiotherapy in the management of POEMS syndrome. Radiation Oncology, 2014, 9, 265. | 1.2 | 18 |
| 83 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. Annals of Hematology, 2014, 93, 1353-1361. | 0.8 | 18 |
| 84 | Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: a single-institution experience. Blood Research, 2017, 52, 184. | 0.5 | 18 |
| 85 | Longlasting Remission of Primary Hepatic Mucosa-associated Lymphoid Tissue (MALT) Lymphoma Achieved by Radiotherapy Alone. Korean Journal of Internal Medicine, 2006, 21, 127. | 0.7 | 18 |
| 86 | Long-term Outcome after Prophylactic Lamivudine Treatment on Hepatitis B Virus Reactivation in Non-Hodgkin's Lymphoma. Yonsei Medical Journal, 2007, 48, 78. | 0.9 | 17 |
| 87 | Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient. Yonsei Medical Journal, 2010, 51, 448. | 0.9 | 17 |
| 88 | High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 73-79. | 2.0 | 17 |
| 89 | The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. The Korean Journal of Hematology, 2010, 45, 269. | 0.7 | 16 |
| 90 | Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease " Consortium for Improving Survival of Lymphoma Study. Acta Haematologica, 2012, 127, 100-104. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 479-483. | 2.0 | 16 |
| 92 | Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification. <i>Annals of Hematology</i> , 2014, 93, 1867-1877. | 0.8 | 16 |
| 93 | Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443. | 0.8 | 16 |
| 94 | Early Cytomegalovirus Reactivation and Expansion of CD56brightCD16dim/â~DNAM1+ Natural Killer Cells Are Associated with Antileukemia Effect after Haploidentical Stem Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2070-2078. | 2.0 | 16 |
| 95 | First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192. | 1.7 | 16 |
| 96 | Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 253-260. | 1.5 | 16 |
| 97 | The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526. | 0.8 | 16 |
| 98 | Statistical Correlations Between Quantifiable Disease Variables and Prognosis in Hematological Malignancy Patients Treated with Itraconazole as An Empirical Antifungal Therapy: A Prospective Multicenter Observational Study in Korea. <i>Blood</i> , 2008, 112, 4028-4028. | 0.6 | 16 |
| 99 | Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. <i>Annals of Hematology</i> , 2012, 91, 249-256. | 0.8 | 15 |
| 100 | Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242. | 0.5 | 15 |
| 101 | High pre-transplant serum ferritin and busulfan-thiotepa conditioning regimen as risk factors for hepatic sinusoidal obstructive syndrome after autologous stem cell transplantation in patients with malignant lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 51-57. | 0.6 | 15 |
| 102 | Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , 2017, 26, 1059-1066. | 1.2 | 15 |
| 103 | Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. <i>Yonsei Medical Journal</i> , 2017, 58, 35. | 0.9 | 15 |
| 104 | Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. <i>Blood Research</i> , 2013, 48, 171. | 0.5 | 14 |
| 105 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Koreaâ€”experience from 110 patients. <i>Annals of Hematology</i> , 2014, 93, 113-121. | 0.8 | 14 |
| 106 | The Effect of Bortezomib on Expression of Inflammatory Cytokines and Survival in a Murine Sepsis Model Induced by Cecal Ligation and Puncture. <i>Yonsei Medical Journal</i> , 2015, 56, 112. | 0.9 | 14 |
| 107 | Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133. | 0.8 | 14 |
| 108 | Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976. | 1.3 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043. | 0.8 | 14 |
| 110 | A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue. <i>Yonsei Medical Journal</i> , 2009, 50, 280. | 0.9 | 13 |
| 111 | Acute promyelocytic leukemia in early pregnancy with translocation t(15;17) and variant PML/RARA fusion transcripts. <i>Cancer Genetics and Cytogenetics</i> , 2009, 188, 48-51. | 1.0 | 13 |
| 112 | Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. <i>International Journal of Hematology</i> , 2010, 92, 510-517. | 0.7 | 13 |
| 113 | Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 117-121. | 1.0 | 13 |
| 114 | Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 617-625. | 0.8 | 13 |
| 115 | The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. <i>Acta Haematologica</i> , 2018, 140, 146-156. | 0.7 | 13 |
| 116 | Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111. | 2.8 | 13 |
| 117 | Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208. | 1.3 | 13 |
| 118 | Therapy-related acute lymphoblastic leukemia with t(9;22)(q34;q11.2): a case study and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2009, 191, 51-54. | 1.0 | 12 |
| 119 | The prognostic role of CD68 and FoxP3 expression in patients with primary central nervous system lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1163-1173. | 0.8 | 12 |
| 120 | Multiparametric approach with diffusion-weighted imaging and dynamic contrast-enhanced MRI: a comparison study for differentiating between benign and malignant bone lesions in adults. <i>Clinical Radiology</i> , 2017, 72, 552-559. | 0.5 | 12 |
| 121 | A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System. <i>British Journal of Haematology</i> , 2018, 181, 707-710. | 1.2 | 12 |
| 122 | Phase II study of R ² CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10. | 3.7 | 12 |
| 123 | Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302. | 1.6 | 12 |
| 124 | Immunosuppressive role of CD11b ⁺ CD33 ⁺ HLA-DR ⁺ myeloid-derived suppressor cells-like blast subpopulation in acute myeloid leukemia. <i>Cancer Medicine</i> , 2020, 9, 7007-7017. | 1.3 | 12 |
| 125 | Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells. <i>Experimental Hematology and Oncology</i> , 2021, 10, 28. | 2.0 | 12 |
| 126 | Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539. | 0.8 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182. | 0.8 | 12 |
| 128 | A Multinational, Open-Label Phase 2 Study Of Ruxolitinib In Asian Patients (Pts) With Primary Myelofibrosis (PMF), Postâ€“Polycythemia Vera MF (PPV-MF), Or Postâ€“Essential Thrombocythemia MF (PET-MF). <i>Blood</i> , 2013, 122, 4086-4086. | 0.6 | 12 |
| 129 | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkinâ€™s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2011, 29, 154-160. | 1.2 | 11 |
| 130 | Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811. | 0.6 | 11 |
| 131 | Clinical features and outcomes of Hodgkinâ€™s lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233. | 0.8 | 11 |
| 132 | The Roles of Radiotherapy and Chemotherapy in the Era of Multimodal Treatment for Early-Stage Nasal-Type Extranodal Natural Killer/T-Cell Lymphoma. <i>Yonsei Medical Journal</i> , 2016, 57, 846. | 0.9 | 11 |
| 133 | Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens. <i>Journal of Korean Medical Science</i> , 2016, 31, 510. | 1.1 | 11 |
| 134 | Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207. | 0.5 | 11 |
| 135 | Updated recommendations for the treatment of venous thromboembolism. <i>Blood Research</i> , 2021, 56, 6-16. | 0.5 | 11 |
| 136 | Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study. <i>Blood</i> , 2019, 134, 1568-1568. | 0.6 | 11 |
| 137 | Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016, 128, 1807-1807. | 0.6 | 11 |
| 138 | Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92312-92323. | 0.8 | 11 |
| 139 | Relapsed or refractory nongastric marginal zone Bâ€“cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829. | 2.0 | 10 |
| 140 | Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. <i>Blood Research</i> , 2013, 48, 24. | 0.5 | 10 |
| 141 | Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. <i>Annals of Hematology</i> , 2014, 93, 211-219. | 0.8 | 10 |
| 142 | The role of upfront autologous stem cell transplantation in highâ€“risk younger patients with primary central nervous system lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 444-453. | 1.2 | 10 |
| 143 | Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 923-929. | 2.0 | 10 |
| 144 | Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 92-95. | 0.6 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation. <i>Supportive Care in Cancer</i> , 2021, 29, 3815-3822. | 1.0 | 10 |
| 146 | The Effect of Bortezomib On Bone Metabolism of Patients with Multiple Myeloma: a Korean Multicenter Prospective Study.. <i>Blood</i> , 2009, 114, 4871-4871. | 0.6 | 10 |
| 147 | Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database. <i>Cancer Research and Treatment</i> , 2020, 52, 1262-1272. | 1.3 | 10 |
| 148 | Management of immune thrombocytopenia: 2022 update of Korean experts recommendations. <i>Blood Research</i> , 2022, 57, 20-28. | 0.5 | 10 |
| 149 | A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. <i>Investigational New Drugs</i> , 2013, 31, 1514-1521. | 1.2 | 9 |
| 150 | Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2490-2496. | 0.6 | 9 |
| 151 | The different roles of molecular classification according to upfront autologous stem cell transplantation in advanced-stage diffuse large B cell lymphoma patients with elevated serum lactate dehydrogenase. <i>Annals of Hematology</i> , 2016, 95, 1491-1501. | 0.8 | 9 |
| 152 | Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. <i>Annals of Hematology</i> , 2016, 95, 55-61. | 0.8 | 9 |
| 153 | Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200. | 0.5 | 9 |
| 154 | Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria. <i>International Journal of Hematology</i> , 2019, 110, 411-418. | 0.7 | 9 |
| 155 | Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)â€”a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , 2019, 9, 83. | 2.8 | 9 |
| 156 | Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90. | 0.7 | 9 |
| 157 | Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWPâ€”164) Tj ETQq1 1 @.784314 ogBT /Ov | | |
| 158 | Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 48-56. | 1.2 | 9 |
| 159 | Stage IV marginal zone Bâ€”cell lymphoma â€” prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Cancer Science</i> , 2010, 101, 2443-2447. | 1.7 | 8 |
| 160 | The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea. <i>Annals of Hematology</i> , 2014, 93, 33-42. | 0.8 | 8 |
| 161 | Induction of apoptosis and differentiation by Na/H exchanger 1 modulation in acute myeloid leukemia cells. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 887-893. | 1.0 | 8 |
| 162 | A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1312-1319. | 2.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | The SMART Anti-hc5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2018, 132, 535-535. | 0.6 | 8 |
| 164 | Clinical Outcomes and Prognostic Factors of Front-Line Autologous Stem Cell Transplantation in Patients with Extranodal NK/T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 2523-2523. | 0.6 | 8 |
| 165 | Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>The Korean Journal of Hematology</i> , 2011, 46, 175. | 0.7 | 7 |
| 166 | Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 1409-1418. | 0.8 | 7 |
| 167 | Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. <i>Annals of Hematology</i> , 2016, 95, 603-611. | 0.8 | 7 |
| 168 | Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies. <i>Blood</i> , 2019, 134, 952-952. | 0.6 | 7 |
| 169 | Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 3166-3166. | 0.6 | 7 |
| 170 | Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2016, 128, 2130-2130. | 0.6 | 7 |
| 171 | Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk. <i>Journal of Clinical Oncology</i> , 2019, 37, 8038-8038. | 0.8 | 7 |
| 172 | Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea. <i>Blood</i> , 2009, 114, 5024-5024. | 0.6 | 7 |
| 173 | Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. <i>Blood</i> , 2012, 120, 3106-3106. | 0.6 | 7 |
| 174 | Acute vesiculobullous hand dermatitis and anagen effluvium in Ganoderma lucidum-induced aplastic crisis. <i>Annals of Hematology</i> , 2013, 92, 1417-1419. | 0.8 | 6 |
| 175 | Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193. | 0.5 | 6 |
| 176 | Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. <i>Leukemia and Lymphoma</i> , 2016, 57, 1389-1397. | 0.6 | 6 |
| 177 | Hematopoietic stem cell mobilization: current status and future perspective. <i>Blood Research</i> , 2017, 52, 79. | 0.5 | 6 |
| 178 | Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. <i>Scientific Reports</i> , 2020, 10, 11649. | 1.6 | 6 |
| 179 | Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020, 103, 1630-1636. | 1.0 | 6 |
| 180 | Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059. | 0.8 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 967-975. | 1.9 | 6 |
| 182 | Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97. | 0.2 | 6 |
| 183 | Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361. | 2.5 | 6 |
| 184 | Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 194-204. | 0.7 | 6 |
| 185 | Ongoing Phase 1a/1b Dose-Finding Study of CWP232291 (CWP291) in Relapsed or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 4501-4501. | 0.6 | 6 |
| 186 | A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618. | 0.8 | 6 |
| 187 | Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation. <i>Radiation Oncology Journal</i> , 2017, 35, 257-267. | 0.7 | 6 |
| 188 | Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1302-1312. | 1.3 | 6 |
| 189 | A der(1;15)(q10;q10) is a rare nonrandom whole-arm translocation in patients with acute lymphoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 132-135. | 1.0 | 5 |
| 190 | Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637. | 0.7 | 5 |
| 191 | Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. <i>Blood Research</i> , 2013, 48, 115. | 0.5 | 5 |
| 192 | Changes in Osteoblastic Activity in Patient Who Received Bortezomib as Second Line Treatment for Plasma Cell Myeloma: A Prospective Multicenter Study. <i>BioMed Research International</i> , 2014, 2014, 1-7. | 0.9 | 5 |
| 193 | Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 465-471. | 0.8 | 5 |
| 194 | Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885. | 1.2 | 5 |
| 195 | The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319. | 0.8 | 5 |
| 196 | Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95. | 0.7 | 5 |
| 197 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721. | 0.6 | 5 |
| 198 | A Case of Panagglutination on Antibody Identification in a Multiple Myeloma Patient Receiving Daratumumab. <i>The Korean Journal of Blood Transfusion</i> , 2016, 27, 164-168. | 0.1 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the <sc>CANDOR</sc> study. <i>British Journal of Haematology</i> , 2022, 198, 988-993. | 1.2 | 5 |
| 200 | Nine-Year Survival of Lymphoblastic Lymphoma Patients. <i>Yonsei Medical Journal</i> , 2006, 47, 466. | 0.9 | 4 |
| 201 | Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2013, 28, 80. | 1.1 | 4 |
| 202 | Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61. | 1.1 | 4 |
| 203 | Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea. <i>BioMed Research International</i> , 2014, 2014, 1-7. | 0.9 | 4 |
| 204 | Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7. | 0.5 | 4 |
| 205 | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412. | 0.6 | 4 |
| 206 | HBsAg-Negative, Anti-HBc“Negative Patients Still Have a Risk of Hepatitis B Virus“Related Hepatitis after Autologous Stem Cell Transplantation for Multiple Myeloma or Malignant Lymphoma. <i>Cancer Research and Treatment</i> , 2018, 50, 1121-1129. | 1.3 | 4 |
| 207 | Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2020, 99, 2149-2157. | 0.8 | 4 |
| 208 | Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. <i>Thrombosis Research</i> , 2020, 194, 45-53. | 0.8 | 4 |
| 209 | A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. <i>Blood</i> , 2008, 112, 3649-3649. | 0.6 | 4 |
| 210 | Association Between Elevated Hemolysis at Diagnosis and Early Mortality and Risk of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with Cytopenia. <i>Blood</i> , 2010, 116, 4241-4241. | 0.6 | 4 |
| 211 | Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2015, 126, 5111-5111. | 0.6 | 4 |
| 212 | Radiotherapy as an effective treatment modality for follicular lymphoma: a single institution experience. <i>Radiation Oncology Journal</i> , 2015, 33, 310. | 0.7 | 4 |
| 213 | Development of <i>Arthrobacter woluwensis</i> Bacteremia in a Patient with Multiple Myeloma: A Case Report and Comprehensive Literature Review. <i>Infection and Chemotherapy</i> , 2012, 44, 205. | 1.0 | 3 |
| 214 | Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores. <i>Annals of Hematology</i> , 2017, 96, 1873-1881. | 0.8 | 3 |
| 215 | Prognostic significance of interventricular septal thickness in patients with AL amyloidosis. <i>Leukemia Research</i> , 2017, 60, 36-43. | 0.4 | 3 |
| 216 | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin“s lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264. | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | Serum albumin and C-reactive protein as significant predictors of non-relapse mortality in lower gastrointestinal graft-versus-host disease. <i>Annals of Hematology</i> , 2020, 99, 1111-1119. | 0.8 | 3 |
| 218 | Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91. | 0.7 | 3 |
| 219 | Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study. <i>Blood</i> , 2020, 136, 32-34. | 0.6 | 3 |
| 220 | Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201. | 0.6 | 3 |
| 221 | Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8058-TPS8058. | 0.8 | 3 |
| 222 | Protein Kinase CK2 Is Associated with Poor Clinical Outcome and Regulates the Expression of Anti-Apoptotic Proteins and PTEN Phosphorylation in Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 2356-2356. | 0.6 | 3 |
| 223 | Human herpesvirus 8-negative effusion-based lymphoma with indolent clinical behavior in an elderly patient: A case report and literature review. <i>Oncology Letters</i> , 2020, 20, 343. | 0.8 | 3 |
| 224 | Multicenter retrospective analysis of patients with chronic lymphocytic leukemia in Korea. <i>Blood Research</i> , 2021, , . | 0.5 | 3 |
| 225 | Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study. <i>Blood</i> , 2020, 136, 11-11. | 0.6 | 3 |
| 226 | Acute Promyelocytic Leukemia with Trisomy 8 and del(9)(q22) after Treatment of Cervical Cancer with Concurrent Chemoradiotherapy: A Case Report. <i>Onkologie</i> , 2011, 34, 388-390. | 1.1 | 2 |
| 227 | 2873Favorable effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with liver cirrhosis. <i>European Heart Journal</i> , 2017, 38, . | 1.0 | 2 |
| 228 | â€œScreening auditâ€™ as a quality assurance tool in good clinical practice compliant research environments. <i>BMC Medical Ethics</i> , 2018, 19, 30. | 1.0 | 2 |
| 229 | Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. <i>Annals of Hematology</i> , 2019, 98, 2273-2281. | 0.8 | 2 |
| 230 | Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e97-e104. | 0.2 | 2 |
| 231 | Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468. | 1.3 | 2 |
| 232 | Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616. | 1.0 | 2 |
| 233 | Predictive Factors of Event-Free Survival at 24 Months in Patients with Peripheral T-Cell Lymphoma: A Retrospective Study. <i>Cancer Research and Treatment</i> , 2022, 54, 613-620. | 1.3 | 2 |
| 234 | YAP and TAZ in Fibroblastic Reticular Cells Support Hematopoiesis and Retention of Lymphocytes in Lymph Nodes. <i>Blood</i> , 2019, 134, 3595-3595. | 0.6 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | A Pilot Study of Alemtuzumab Plus Combination Chemotherapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphomas.. Blood, 2006, 108, 4717-4717. | 0.6 | 2 |
| 236 | Efficacy of ICT with Deferasirox in Transfusional Iron Overloaded Patients with MDS or AA.. Blood, 2009, 114, 3810-3810. | 0.6 | 2 |
| 237 | The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.. Blood, 2010, 116, 1791-1791. | 0.6 | 2 |
| 238 | Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas. Blood, 2011, 118, 1642-1642. | 0.6 | 2 |
| 239 | Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7532-7532. | 0.8 | 2 |
| 240 | TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL). Blood, 2021, 138, 3545-3545. | 0.6 | 2 |
| 241 | An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial. Blood, 2020, 136, 2-3. | 0.6 | 2 |
| 242 | An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884. | 1.1 | 2 |
| 243 | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Research and Treatment, 2023, 55, 325-333. | 1.3 | 2 |
| 244 | Realá€world data on prognostic value of measurable residual disease assessment by fragment analysis or nextá€generation sequencing in multiple myeloma. British Journal of Haematology, 2022, , . | 1.2 | 2 |
| 245 | Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. International Journal of Hematology, 2022, 116, 553-562. | 0.7 | 2 |
| 246 | Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma. Scientific Reports, 2022, 12, 8287. | 1.6 | 2 |
| 247 | Transplantation of peripheral blood stem cells mobilized by intensified consolidation and granulocyte colony-stimulating factor in acute leukemia. Yonsei Medical Journal, 2001, 42, 65. | 0.9 | 1 |
| 248 | Two Cases of Acquired Hemophilia A Successfully Treated with Oral Steroid or Danazol. The Korean Journal of Hematology, 2005, 40, 58. | 0.7 | 1 |
| 249 | ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography in symmetrically enlarged axillary and inguinal lymph nodes of Ofuji's papuloerythroderma. Leukemia and Lymphoma, 2012, 53, 511-513. | 0.6 | 1 |
| 250 | Clinical Outcomes and Prognostic Factors of Empirical Antifungal Therapy with Itraconazole in the Patients with Hematological Malignancies: A Prospective Multicenter Observational Study in Korea. Yonsei Medical Journal, 2014, 55, 9. | 0.9 | 1 |
| 251 | Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma. Supportive Care in Cancer, 2021, 29, 4969-4977. | 1.0 | 1 |
| 252 | Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. Current Problems in Cancer, 2021, 46, 100788. | 1.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 253 | Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis. Korean Journal of Internal Medicine, 2021, 36, 1181-1189. | 0.7 | 1 |
| 254 | mTOR Inhibitor Rapamycin Interacts Synergistically with Farnesyltransferase Inhibitor FTI-277 To Induce Growth Inhibition in Human Leukemia Cells.. Blood, 2007, 110, 1821-1821. | 0.6 | 1 |
| 255 | Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. Blood, 2008, 112, 5184-5184. | 0.6 | 1 |
| 256 | Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients.. Blood, 2009, 114, 2284-2284. | 0.6 | 1 |
| 257 | The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. Blood, 2009, 114, 4902-4902. | 0.6 | 1 |
| 258 | Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study.. Blood, 2010, 116, 1790-1790. | 0.6 | 1 |
| 259 | Low Psoas Muscle/BMI Ratio Is a Bad Prognostic Index Of Non-Relapse Survival After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 3326-3326. | 0.6 | 1 |
| 260 | Risk Factors For The Development Of Severe Bacterial Infection In Patients With Multiple Myeloma During Chemotherapy With Bortezomib Containing Regimens. Blood, 2013, 122, 5370-5370. | 0.6 | 1 |
| 261 | Autophagy Inhibition Overcomes Resistance to Cytosine Arabinoside in Acute Myeloid Leukemia Cells through Inducing Autophagic Cell Death and Intrinsic Pathway Apoptosis. Blood, 2014, 124, 909-909. | 0.6 | 1 |
| 262 | Primary Bilateral Adrenal Non-Hodgkin's Lymphoma Presented with Adrenal Insufficiency: A Case Report. Endocrinology and Metabolism, 2011, 26, 101. | 1.3 | 1 |
| 263 | A Case Report of Posttransplant Lymphoproliferative Disorders Successfully Treated with R-CHOP in Korea. The Korean Journal of Hematology, 2008, 43, 106. | 0.7 | 1 |
| 264 | Elevated preoperative serum level of tumor markers CEA and CA 15 ³ in breast cancer patients. Journal of Clinical Oncology, 2006, 24, 621-621. | 0.8 | 1 |
| 265 | Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. Blood, 2009, 114, 3751-3751. | 0.6 | 1 |
| 266 | Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. Blood, 2010, 116, 3536-3536. | 0.6 | 1 |
| 267 | PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2012, 30, TPS8118-TPS8118. | 0.8 | 1 |
| 268 | A Phase 1/2, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan As a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: Result of Phase 1 Trial. Blood, 2012, 120, 1937-1937. | 0.6 | 1 |
| 269 | Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. Blood, 2013, 122, 3720-3720. | 0.6 | 1 |
| 270 | Delta-Neutrophil Index Is a Useful Indicator for Initiation of Peripheral Blood Stem Cell Collection in Chemo-Mobilized Patients. Blood, 2014, 124, 2457-2457. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 271 | Future Development for the Board Licensing Examination of Internal Medicine. Korean Journal of Medicine, 2017, 92, 109-111. | 0.1 | 1 |
| 272 | Acquired Hemophilia A. Clinical & Experimental Thrombosis and Hemostasis, 2019, 5, 11-14. | 0.2 | 1 |
| 273 | Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. Blood, 2020, 136, 27-28. | 0.6 | 1 |
| 274 | COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 6-7. | 0.6 | 1 |
| 275 | Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study. Blood, 2020, 136, 30-31. | 0.6 | 1 |
| 276 | Population pharmacokinetics of amikacin in Korean adult patients. Clinical Pharmacology and Therapeutics, 2005, 77, P86-P86. | 2.3 | 0 |
| 277 | Population pharmacokinetics of aminophylline in Korean preterm infants using TDM data. Clinical Pharmacology and Therapeutics, 2005, 77, P86-P86. | 2.3 | 0 |
| 278 | A Case of Serum Amino Acid Disturbance with Hyperammonemia in Patient with Primary Amyloidosis. The Korean Journal of Hematology, 2005, 40, 54. | 0.7 | 0 |
| 279 | Significance of Notch Expression in Acute Myeloid Leukemia. The Korean Journal of Hematology, 2008, 43, 9. | 0.7 | 0 |
| 280 | A novel t(1;12)(q21;q24) in a patient with myelodysplastic syndrome. Annals of Hematology, 2010, 89, 513-516. | 0.8 | 0 |
| 281 | Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC) Tj ETQq1 1 0.784314ogBT /Over | 0.7 | 0 |
| 282 | DOPO31 Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn's disease patients. Journal of Crohn's and Colitis, 2017, 11, S45-S46. | 0.6 | 0 |
| 283 | P3830Favorable neurological outcomes of left atrial appendage occlusion versus non-vitamin K antagonist oral anticoagulants after stroke in atrial fibrillation. European Heart Journal, 2018, 39, . | 1.0 | 0 |
| 284 | P5143The increased risk of stroke, bleeding and mortality with new-onset atrial fibrillation in critically ill patients: a nationwide cohort study. European Heart Journal, 2018, 39, . | 1.0 | 0 |
| 285 | P5391Statin and clinical outcome in patients >75 years without atherosclerotic cardiovascular disease. European Heart Journal, 2018, 39, . | 1.0 | 0 |
| 286 | Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma. Korean Journal of Internal Medicine, 2021, 36, S245-S252. | 0.7 | 0 |
| 287 | Isatuximab plus carfilzomib and dexamethasone in east Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.. Journal of Clinical Oncology, 2021, 39, e20015-e20015. | 0.8 | 0 |
| 288 | Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. Current Problems in Cancer, 2021, 46, 100786. | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 289 | Screening Tests for Early Diagnosis of Multiple Myeloma and Related Plasma Cell Disorders. Korean Journal of Medicine, 2021, 96, 371-381. | 0.1 | 0 |
| 290 | Dose-intensive CHOP chemotherapy followed by radiation for localized NK/T-cell lymphoma. Journal of Clinical Oncology, 2004, 22, 6716-6716. | 0.8 | 0 |
| 291 | A Case of Bronchiolitis Obliterans Organizing Pneumonia Following CHOP Chemotherapy and Filgrastim Use in a Patient with Diffuse Large B-cell Lymphoma. Tuberculosis and Respiratory Diseases, 2005, 59, 561. | 0.7 | 0 |
| 292 | Extended Study for Topotecan, Idarubicin, and Intermediate-Dose Cytarabine Combination Chemotherapy in Patients with Refractory or Relapsed Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome.. Blood, 2005, 106, 4609-4609. | 0.6 | 0 |
| 293 | Attenuated Dose of Idarubicin for the Elderly De Novo Acute Myeloid Leukemia with Normal Karyotype.. Blood, 2005, 106, 4608-4608. | 0.6 | 0 |
| 294 | RNA Silencing of Aurora Kinase Genes Sensitizes Human Leukemia Cells to the Ara-C-Induced Cell Death Via Caspase-Independent Pathway.. Blood, 2005, 106, 2468-2468. | 0.6 | 0 |
| 295 | Prognostic Implications of the Immunophenotype in Biphenotypic Acute Leukemia.. Blood, 2006, 108, 2319-2319. | 0.6 | 0 |
| 296 | A Report of AIDS-Related Lymphoma (ARL) in Korea.. Blood, 2006, 108, 4687-4687. | 0.6 | 0 |
| 297 | Clinical implication of distinction from clinical features and treatment outcome of malignant lymphoma in Korean childhood and young adult. Journal of Clinical Oncology, 2007, 25, 18534-18534. | 0.8 | 0 |
| 298 | Complete Remission Status at Autologous Transplantation Is an Important Prognostic Factor in Multiple Myeloma Patients Received Upfront Single Autologous Transplantation.. Blood, 2007, 110, 955-955. | 0.6 | 0 |
| 299 | Central Nervous System Relapses in Patients with Diffuse Large B Cell Lymphoma: Multicenter Retrospective Analysis in Korea. Blood, 2008, 112, 5314-5314. | 0.6 | 0 |
| 300 | Aurora Kinase Inhibition Enhances the Chemotherapy-Induced Myeloid Leukemia Cell Death through Different Mechanism According to the Chemotherapeutic Agents. Blood, 2008, 112, 2644-2644. | 0.6 | 0 |
| 301 | Level of Myeloperoxidase Expression as a Crucial Determinant of Sensitivity of Myeloid Leukemia Cells to Parthenolide-Induced Apoptosis. Blood, 2008, 112, 2945-2945. | 0.6 | 0 |
| 302 | Primary chemotherapy, stereotactic radiosurgery, or whole brain radiotherapy in non-small cell lung cancer (NSCLC) patients with asymptomatic brain metastases. Journal of Clinical Oncology, 2009, 27, e19063-e19063. | 0.8 | 0 |
| 303 | Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.. Blood, 2009, 114, 5009-5009. | 0.6 | 0 |
| 304 | Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.. Blood, 2009, 114, 4999-4999. | 0.6 | 0 |
| 305 | Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. Blood, 2009, 114, 4881-4881. | 0.6 | 0 |
| 306 | Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. Blood, 2009, 114, 5017-5017. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 307 | Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. Blood, 2009, 114, 4992-4992. | 0.6 | 0 |
| 308 | Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. Blood, 2009, 114, 4298-4298. | 0.6 | 0 |
| 309 | Low Absolute Lymphocyte Count Predicts Chemotherapy Response and Survival In Peripheral T-Cell Lymphoma, NOS. Blood, 2010, 116, 3135-3135. | 0.6 | 0 |
| 310 | A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri.. Blood, 2010, 116, 1125-1125. | 0.6 | 0 |
| 311 | Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 547 10 B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.. Blood, 2010, 116, 1786-1786. | 0.6 | 0 |
| 312 | Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 547 10 Blood, 2010, 116, 1765-1765. | 0.6 | 0 |
| 313 | Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. Blood, 2010, 116, 5084-5084. | 0.6 | 0 |
| 314 | Circulating Exosomal MicroRNA-21 As a Potential Biomarker That May Predict Response to Azacitidine Treatment in Myelodysplastic Syndromes,. Blood, 2011, 118, 3804-3804. | 0.6 | 0 |
| 315 | Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. Blood, 2011, 118, 1990-1990. | 0.6 | 0 |
| 316 | Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866. | 0.6 | 0 |
| 317 | Early Response to Bortezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. Blood, 2011, 118, 5138-5138. | 0.6 | 0 |
| 318 | Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 5273-5273. | 0.6 | 0 |
| 319 | Pretransplant Parathyroid Hormone Level Has No Correlation with Platelet Recovery After Stem Cell. Blood, 2012, 120, 4495-4495. | 0.6 | 0 |
| 320 | High Dose Etoposide Plus G-CSF As an Effective Mobilization Regimen in Patients with NHL Previously Treated with R-CHOP or CHOP Chemotherapy. Retrospective Multicenter Study. Blood, 2012, 120, 1917-1917. | 0.6 | 0 |
| 321 | High Serum Level of APRIL Is Related to Increased Risk of Acute Gvhd. Blood, 2012, 120, 4161-4161. | 0.6 | 0 |
| 322 | Risk of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis. Blood, 2012, 120, 1273-1273. | 0.6 | 0 |
| 323 | Clinical Characteristics and Outcomes Of Waldeyer's Ring Lymphoma: Nation-Wide Study In Korea. Blood, 2013, 122, 4332-4332. | 0.6 | 0 |
| 324 | The Role Of Modified Glasgow Prognostic Score As Predictor In Diffuse Large B Cell Lymphoma Treated With The R-CHOP Regimen. Blood, 2013, 122, 4307-4307. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 325 | Prognostic Role Of Monoclonal and Polyclonal Gammopathy Measured By Serum Free Light Chain and Immunofixation In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 5112-5112. | 0.6 | 0 |
| 326 | Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. Blood, 2013, 122, 3201-3201. | 0.6 | 0 |
| 327 | Clinical Limitations of Surveillance Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography According to Histologic Subtypes in Patients with Malignant Lymphoma Who Achieved Complete Remission. Blood, 2014, 124, 1736-1736. | 0.6 | 0 |
| 328 | Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4421-4421. | 0.6 | 0 |
| 329 | The New Prognostic Model Using Whole Blood Epstein-Barr Virus-DNA Positivity and Low Absolute Lymphocyte Count in Patients with Primary Central Nerve System Lymphoma. Blood, 2014, 124, 3014-3014. | 0.6 | 0 |
| 330 | Salvage Chemotherapy Followed By Autologous Peripheral Stem Cell Transplantation for Relapsed Acute Promyelocytic Leukemia; A Single Center Experience. Blood, 2014, 124, 4000-4000. | 0.6 | 0 |
| 331 | Treatment Outcome and Prognostic Factors of Korean Patients with Chronic Lymphocytic Leukemia: Multicenter Retrospective Study. Blood, 2014, 124, 5669-5669. | 0.6 | 0 |
| 332 | Post-Autotransplant Hepatitis B Virus (HBV) Reactivation in Lymphoma and Multiple Myeloma Patients with Hepatitis B Surface Antigen-Positive or Resolved HBV Infection. Blood, 2014, 124, 1196-1196. | 0.6 | 0 |
| 333 | Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 5151-5151. | 0.6 | 0 |
| 334 | Upfront Autologous Stem Cell Transplantation Overcome the poor Prognosis of Non-Germinal Center Subtype of diffuse Large B-Cell Lymphoma in Patients with Advanced Stage and Elevated Serum Lactate Dehydrogenase. Blood, 2014, 124, 3998-3998. | 0.6 | 0 |
| 335 | a Randomized, Controlled, Prospective Study for Efficacy of Micafungin Versus Itraconazole As Empirical Antifungal Therapy for Febrile Neutropenic Patients with Acute Leukemia. Blood, 2014, 124, 3729-3729. | 0.6 | 0 |
| 336 | Prognostic Factors in Adult Patients with Acute Promyelocytic Leukemia Receiving ATRA-Based Treatment. Blood, 2014, 124, 5274-5274. | 0.6 | 0 |
| 337 | A New Prognostic Index for Multiple Myeloma Patients in the Era of Novel Agents. Blood, 2014, 124, 3472-3472. | 0.6 | 0 |
| 338 | A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents. Blood, 2015, 126, 4185-4185. | 0.6 | 0 |
| 339 | Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. Blood, 2015, 126, 4789-4789. | 0.6 | 0 |
| 340 | A Prognostic Scoring System for Patients with Multiple Myeloma Who Were Classified Stage II By Revised International Staging System. Blood, 2016, 128, 3284-3284. | 0.6 | 0 |
| 341 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414. | 0.6 | 0 |
| 342 | The Role of MYC and BCL-2 Double Expression the in DLBCL Patients with Advanced Stage and Elevated LDH Who Received Upfront ASCT after R-CHOP. Blood, 2016, 128, 4219-4219. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 343 | The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445. | 0.6 | 0 |
| 344 | Clinical Outcomes in Patients with Diffuse Large B Cell Lymphoma with Partial Responses to First-Line R-CHOP Chemotherapy: Prognostic Value of Secondary IPI Scores and FDG-PET. <i>Blood</i> , 2016, 128, 4205-4205. | 0.6 | 0 |
| 345 | Two Cases of Chickenpox Developed from an Immunocompromised Patient with Localized Herpes Zoster. <i>Korean Journal of Healthcare-Associated Infection Control and Prevention</i> , 2019, 24, 103. | 0.1 | 0 |
| 346 | Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era. <i>Blood</i> , 2019, 134, 4002-4002. | 0.6 | 0 |
| 347 | Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study. <i>Blood</i> , 2020, 136, 14-14. | 0.6 | 0 |
| 348 | Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2020, 136, 1-1. | 0.6 | 0 |
| 349 | Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies. <i>Blood</i> , 2020, 136, 42-43. | 0.6 | 0 |
| 350 | Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , . | 0.2 | 0 |
| 351 | Dose-intensive CHOP chemotherapy followed by radiation for localized NK/T-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 6716-6716. | 0.8 | 0 |
| 352 | Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). <i>International Journal of Hematology</i> , 2022, , 1. | 0.7 | 0 |